Catalyst Dossier · compiled by CeliA 🧫
NeuroSense Therapeutics Ltd. (NRSN)
Pharmaceutical Preparations · market cap $28M · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-12-01
NDA Filing
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
NeuroSense Therapeutics Ltd. (NRSN) is a micro-cap clinical-stage pharmaceutical company with 17 employees and a market cap of approximately $28M at ~$0.70/share. Its pipeline centers on PrimeC, a fixed-dose combination asset in Phase 2 for Alzheimer's Disease, and a separate fixed-dose combination of Ciprofloxacin/Celecoxib in Phase 2 for ALS. No near-term catalysts are currently calendared.
The catalyst path
- 2026-12-01NDA Filingimp 6/10
- 2026-12-31NDA Filingimp 6/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PrimeC | Phase 2 | Alzheimer Disease |
Price & technical context
3-month
-52.7%
6-month
-58.8%
12-month
-74.3%
52-wk range
$0.33–$1.27
vs 50-day MA
-33.2%
vs 200-day MA
-54.6%
Realized vol
85.9%
Max drawdown
-86.7%
Daily closes through 2026-09-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NRSN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.